Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.
Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.
Lupin President - India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.
On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name "FluGuard" for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.
Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Covid-19 Cases Rising Again: WHO Issues Urgent Alert On Potentially Severe Variants Covid-19 Still Driving High Mortality Rate In This Country Biden Returns To White House After Exiting US Presidential Race 2 French Rafale Jets Collide Mid-Air, Instructor, Pilot Missing Ayatollah Khamenei Warns Of "Divine Wrath" If Iran Backs Down Against Israel 9 Arrested For Violence At Kolkata Hospital Where Doctor Was Raped-Murdered Musk Has A Favourite Interview Question That Experts Say Can Catch Liars Assam Cops Find "IED-Like Material" After Terror Group Says It Planted Bombs Will Build Education System So That Youngsters Do Not Go Abroad: PM Modi Track Latest News Live on NDTV.com and get news updates from India and around the world.